Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PROTRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PROTRIPTYLINE HYDROCHLORIDE.
IMIPRAMINE PAMOATE vs PROTRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
None Documented
None Documented
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant